GoodRx Holdings, Inc. $GDRX Shares Sold by Lakewood Capital Management LP

Lakewood Capital Management LP cut its position in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) by 64.1% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,492,274 shares of the company’s stock after selling 2,665,000 shares during the quarter. Lakewood Capital Management LP’s holdings in GoodRx were worth $6,312,000 as of its most recent filing with the SEC.

Several other large investors also recently bought and sold shares of the company. Cetera Investment Advisers purchased a new position in shares of GoodRx in the second quarter valued at $50,000. Walled Lake Planning & Wealth Management LLC purchased a new stake in shares of GoodRx in the second quarter valued at about $55,000. Tower Research Capital LLC TRC raised its position in shares of GoodRx by 202.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 11,327 shares of the company’s stock worth $56,000 after purchasing an additional 7,580 shares during the last quarter. Bayesian Capital Management LP purchased a new stake in GoodRx in the 2nd quarter valued at approximately $69,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in GoodRx during the 3rd quarter valued at $79,000. Institutional investors and hedge funds own 63.77% of the company’s stock.

Wall Street Analysts Forecast Growth

GDRX has been the subject of a number of analyst reports. Mizuho cut their price target on GoodRx from $4.00 to $3.00 and set a “neutral” rating for the company in a report on Friday, February 27th. Barclays began coverage on shares of GoodRx in a research note on Monday, December 8th. They issued an “underweight” rating and a $3.00 target price for the company. Jefferies Financial Group downgraded shares of GoodRx to a “hold” rating in a report on Thursday, January 22nd. Weiss Ratings reissued a “sell (d)” rating on shares of GoodRx in a research report on Tuesday, December 23rd. Finally, Wall Street Zen lowered shares of GoodRx from a “buy” rating to a “hold” rating in a research report on Sunday, January 25th. Five investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, GoodRx currently has a consensus rating of “Hold” and an average target price of $3.98.

GoodRx Stock Performance

NASDAQ:GDRX opened at $2.24 on Friday. The firm’s fifty day simple moving average is $2.41 and its 200 day simple moving average is $3.13. The company has a current ratio of 2.61, a quick ratio of 2.61 and a debt-to-equity ratio of 0.78. GoodRx Holdings, Inc. has a twelve month low of $1.77 and a twelve month high of $5.81. The firm has a market capitalization of $760.32 million, a price-to-earnings ratio of 24.89, a PEG ratio of 1.53 and a beta of 1.52.

GoodRx (NASDAQ:GDRX) last announced its quarterly earnings results on Wednesday, February 25th. The company reported $0.09 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.09. GoodRx had a return on equity of 9.31% and a net margin of 3.82%.The firm had revenue of $194.79 million during the quarter, compared to the consensus estimate of $193.27 million. During the same period in the prior year, the firm earned $0.09 EPS. The firm’s quarterly revenue was down 1.9% compared to the same quarter last year. As a group, equities research analysts expect that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current fiscal year.

GoodRx Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.